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ABSTRACT
The consumption of sugar-free foods is growing because of their low-calorie content and the health concerns about products with high sugar
content. Sweeteners that are frequently several hundred thousand times sweeter than sucrose are being consumed as sugar substitutes. Although
nonnutritive sweeteners (NNSs) are considered safe and well tolerated, their effects on glucose intolerance, the activation of sweet taste receptors,
and alterations to the composition of the intestinal microbiota are controversial. This review critically discusses the evidence supporting the effects
of NNSs, both synthetic sweeteners (acesulfame K, aspartame, cyclamate, saccharin, neotame, advantame, and sucralose) and natural sweeteners
(NSs; thaumatin, steviol glucosides, monellin, neohesperidin dihydrochalcone, and glycyrrhizin) and nutritive sweeteners (polyols or sugar alcohols)
on the composition of microbiota in the human gut. So far, only saccharin and sucralose (NNSs) and stevia (NS) change the composition of the gut
microbiota. By definition, a prebiotic is a nondigestible food ingredient, but some polyols can be absorbed, at least partially, in the small intestine
by passive diffusion: however, a number of them, such as isomaltose, maltitol, lactitol, and xylitol, can reach the large bowel and increase the
numbers of bifidobacteria in humans. Further research on the effects of sweeteners on the composition of the human gutmicrobiome is necessary.
Adv Nutr 2019;10:S31–S48.
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Introduction
The consumption of sugars, mainly as sucrose and glucose-
fructose syrups, has dramatically increased worldwide and
growing concerns about their adverse effects on health and
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metabolic diseases, such as metabolic syndrome, cardiovas-
cular diseases, and type 2 diabetes (T2D), have motivated
people to reduce the consumption of free sugars. Sweeteners
are sugar substitutes that mimic the sweet taste of sugar but
have a negligible impact on energy intake (1, 2).
The sweetness of sweeteners is measured in relation to
the reference sugar sucrose. Biologically, the perception of
sweetness occurs through the receptors on the taste buds,
which are coupled to G proteins [taste receptor types 1 and 2
(T1R1 and T1R2, respectively)] that form part of the C class
of proteins (3).
Nonnutritive sweeteners (NNSs) are defined as sweeten-
ing agents that have a higher sweetening intensity and lower
calorie content per gram compared with caloric or nutritive
sweeteners such as sucrose or corn syrup. NNSs can be
of synthetic or natural origin, the latter being increasingly
consumed (4, 5). Low-calorie sweeteners (LCSs), such as
polyols or sugar alcohols and other new sugars, are low-
digestible carbohydrates derived from the hydrogenation of
their sugar or syrup sources. Sugar alcohols are ∼25–100%
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as sweet as sugar. Sugar alcohols are slightly lower in calories
than sugar and do not promote tooth decay or cause a sudden
increase in blood glucose (6).
Both NNSs and LCSs are consumed not only by people
with diabetes but also by the general population, because
they are used as ingredients in many reduced-calorie foods
such as soft drinks, dairy products, powdered drink mixes,
baked goods, desserts, candy, chocolates, puddings, canned
foods, jams and jellies, and confectionery chewing gums. In
addition, they can be used as tabletop sweeteners at home, in
cafeterias, and in restaurants (6).
The US FDA approval process for sweeteners includes
determining the probable intake amounts, the cumulative
effects of the sweetener from all of its uses, and toxicology
studies in animals. In addition, in the European Union (EU),
the European Food Safety Authority (EFSA), and Codex
Alimentarius have evaluated and confirmed that NNSs and
LCSs are safe for human consumption and do not cause
cancer or other health-related problems as long as they are
consumedwithin theAcceptable Daily Intake (ADI). To date,
the FDA has approved 6 high-intensity artificial sweeteners
for foods and drinks: acesulfame potassium (acesulfame K),
aspartame, neotame, saccharin, sucralose, and advantame.
In addition, 3 NNSs of natural origin—steviol glycosides,
thaumatin, and luo han guo fruit extracts—have been ap-
proved by the FDA (6). The EU EFSA has approved 11 NNSs
for human consumption: acesulfame K (E-950), advan-
tame (E-969), aspartame (E-951), aspartame-acesulfame salt
(E-962), cyclamic acid and its sodium and calcium salts
(E-952), neohesperidin dihydrochalcone (E-959), neotame
(E-961), saccharin (E-954), steviol glycosides (E-960, includ-
ing 10 different glycosides), sucralose (E-955), and thaumatin
(E-957) (7).
Food-use–approved polyols are low-calorie carbohydrates
with a sweet taste used, volume-for-volume, as a substitute
for sucrose and other free sugars. They include erythritol, hy-
drogenated starch hydrolysates (sometimes listed as maltitol
syrup, hydrogenated glucose syrup, polyglycitol, polyglucitol,
or simply HSH), isomaltose, lactitol, maltitol, mannitol,
sorbitol, and xylitol. In the United States, the FDA classifies
some polyols as Generally Recognized As Safe, whereas
others are approved food additives. The approved LCSs in the
EU include the following: sorbitol and sorbitol syrup (E420),
mannitol (E-421), isomaltose (E-953), polyglycitol syrup
(E-964), maltitol and maltitol syrup (E-965), lactitol (E-966),
xylitol (E-967), and erythritol (E-968) (7).
Although the FDA, EFSA, Codex Alimentarius, andmany
national authorities have recognized that both NNSs and
LCSs are generally safe andwell tolerated, there is controversy
about the effects of the sweeteners on human health (2). The
consumption of NNSs, mainly in diet sodas, has been related
to an increased risk of obesity, metabolic syndrome, and T2D
(8–12), although some studies did not find any association
(13, 14). The consumption of typically used nonnutritive
artificial sweetener formulations drives the development of
glucose intolerance through the induction of compositional
and functional alterations to the intestinalmicrobiota (15). In
contrast, the consumption of NNSs reduces blood glucose,
which is attributed to the lower carbohydrate load rather
than the activation of sweet taste receptors (16). In some
people, the excessive consumption of polyols may cause
gastrointestinal symptoms such as gas or laxative effects,
similar to the gastrointestinal reaction to beans and certain
high-fiber foods. Such symptoms depend on an individual’s
sensitivity and the other foods eaten at the same time (17).
Intestinal microbial communities play a significant role
in human health and disease; indeed, the intestinal micro-
biome is involved in metabolism, immunity, growth, and
the fermentation of undigested carbohydrates (18). More
importantly, the gut microbiota cooperates with the immune
system, providing signals to promote the maturation of
immune cells and the induction of susceptibility to many
pathophysiologic conditions (19). The composition and
function of the microbiome are modulated and can be
rapidly altered by diet (20). The importance of studying the
microbiome as a potential link between NNS/nonnutritive
artificial sweetener and LCS consumption and its effects on
human health is currently being addressed because of the
well-known interactions between human health, diet, and
intestinal microbiota. However, there are many gaps in the
evidence related to the health effects of NNSs and LCSs
in both healthy and nonhealthy populations. Therefore, we
critically reviewed the literature describing the impact of
NNSs and LCSs on the gut microbiota.
Current Status of Knowledge
Effects of intensive sweeteners on the gut microbiota
Intensive sweeteners have negligible caloric content and
high-power sweetening and are used in low quantities in
foods. All of them have been classified in synthetic and
natural sweeteners (5). Their structures and ADI, as well as
their main biological effects, are summarized in Table 1.
Synthetic sweeteners.
Acesulfame K. Acesulfame is an acidic cyclic sulfonamide
and acesulfameK (E-950) is the potassium salt of acesulfame.
Acesulfame K is metabolized by the human body and has an
ADI of 15 mg/kg body weight (5, 21).
Acesulfame K decreases glucose fermentation by the
cecal microbiota in Cara rats, suggesting that sweeteners
might affect glucose transport systems (22). The effects
of acesulfame K were not associated with gut microbial
functional capability (23).
A study in mice that received distilled water and
15 mg acesulfame K/kg showed that the total bacteria,
Firmicutes, Bacteroidetes, and several other genera were
similar between the 2 groups, establishing that the con-
sumption of acesulfame K had few effects on gut microbiota
and their metabolism in mice (24). In contrast, Bian et al.
(25) found the opposite; consuming acesulfame K for 4 wk
perturbed the gut microbiota of CD-1mice. Bacteroideswere
highly increased in acesulfame K–treated male mice and
significant changes inAnaerostipes and Sutterella populations
occurred as well. Conversely, in female mice, acesulfame K
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TABLE 1 Structure, ADI, and biological effects of natural and synthetic sweeteners1
Sweetener ADI, mg · kg−1 · d−1 Structure Biological effects
Acesulfame K (E-950) 15 C4H4KNO4S Acesulfame K undergoes metabolization by the human body, which the majority of
studies describe as innocuous. No effects on body weight or glucose tolerance.
Aspartame (E-951) 40 C14H18N2O5 Aspartame, a combination of amino acids, namely L-phenylalanine and L-aspartic
acid, and connected through methyl ester bonds, is rapidly absorbed. This
compound is safe and without toxicity in gene mutations.
Neotame (E-961) 2 C20H30N2O5 Neotame is a sweetener with a very similar structure to aspartame. It is safe for
patients with phenylketonuria, but also safe for diabetics. With regard to its
metabolization, half of the ingested neotame is not absorbed and excreted
through the feces, whereas the other half is excreted in the urine as de-esterified
neotame.
Advantame (E-969) 5 C24H30N2O7 Advantame is obtained through chemical synthesis from aspartame and isovanillin
and is a source of phenylalanine. This compound is nontoxic or carcinogenic and
there are no risks of its consumption as a food additive.
Cyclamate (E-952) 11 C6H12NNaO3S Cyclamate is prepared by the sulfonation of cyclohexylamine (toxic compound).
The EU has approved its use in food, although the FDA removed its GRAS status
in 1969 and completely banned it in 1970. No effects on body weight or glucose
tolerance.
Saccharin (E-954) 5 C7H5NO3S Saccharin is excreted through urine and is not metabolized in the body, although it
can cross the placenta and can be transferred through breast milk. Its
consumption is not recommended for pregnant or breastfeeding women.
Sucralose (E-955) 5 C12H22O11 Sucralose is obtained by substitution of the 3-hydroxyl groups in sucrose.
Approximately 11–27% of ingested sucralose is absorbed from the gut and is
excreted in the kidneys. Sucralose is safe.
Steviol glucosides (E-960) 4 Variable Steviol glycosides are molecules extracted from the leaves of Stevia rebaudiana
Bertoni. Colonic bacteria converts them into steviol glucoronides to finally be
excreted through urine. The consumption of these molecules is safe.
Glycyrrhizin NA C42H62O16 Glycyrrhizin is a triterpenoid saponin that is obtained from the roots and rhizome
of Glycyrrhiza glabra. In the EU, its consumption is considered safe with a limit of




4 C28H36O15 Neohesperidin dihydrochalcone is a seminatural sweetener that comes from the
skin of the immature fruits of Citrus aurantium L. Approved in the EU since 1994
but not in the United States.
Thaumatin (E-957) 50 — Thaumatin is a mixture of compounds extracted from the Thaumatococcus danielli
Bennett plant. As a sweetener, it is approved both in the EU and the United
States, where it is considered GRAS.
1ADI, Acceptable Daily Intake; EU, European Union; GRAS, Generally Recognized As Safe; NA, not available.
and Clostridium. Those changes in the populations of gut
microbiota after the consumption of acesulfame K indicate
sex-specific effects (25).
The principal reason for these contradictory results is
likely related to the acesulfame K dose administered in each
study; in the first study, a dose of 15 body weight mg · kg−1 ·
d−1 was used (24), and in the second study, a dose of 37.5
body weight mg · kg−1 · d−1 was used (25). With regard
to human consumption, the Uebanso et al. (24) study used
the maximum ADI level, whereas the Bian et al. (25) study
exceeded by more than twice the ADI recommendation.
Indeed, this work might be physiologically irrelevant (25).
Aspartame. Aspartame (E-951) is a dipeptide consisting
of aspartic acid and phenylalanine, with the carboxyl ter-
minal group of the latter being methylated (N-l-α-aspartyl-
l-phenylalanine 1-methyl ester). It is ∼200 times sweeter
than sucrose. The metabolism and fate of aspartame are
dominated by presystemic hydrolysis to the constituent parts,
with little or no parent compound entering the general
circulation. According to EU regulation no. 1169/2011, all
food that uses aspartame has to have a visible label containing
the words “contains aspartame (source of phenylalanine).”
The ADI for aspartame is 40 mg/kg body weight (5).
A 400-mg dose of aspartame did not affect the peak
insulin concentrations in subjects with or without diabetes
but did cause a decrease in plasma glucose concentrations
(26). Tordoff and Alleva (27) compared the consumption
of aspartame and high-fructose corn syrup and concluded
that aspartame reduces sugar intake. Although we have a
huge quantity of information with regard to aspartame safety
in humans, few of those studies focused on the effects of
aspartame intake on the composition of gut microbiota.
In rats, the impact of chronic low-dose aspartame
consumption on anthropometric, metabolic, and microbial
variables was tested in a diet-induced obesity model. The
rats were randomly divided into 4 groups that received
the following for 8 wk: a standard feed pellet–diet group
(12% of kilocalories from fat) with ad libitum water or
5–7 mg aspartame · kg body weight−1 . d−1 in drink-
ing water and a high-fat-diet group (60% of kilocalories
from fat) with ad libitum water or 5–7 mg · kg body
weight−1 · d−1 in drinking water. Aspartame consumption
increased the fasting glucose concentrations in both the









istoria de las C
iencias user on 29 O
ctober 2019
standard feed pellet diet and high-fat groups independent
of body composition. A metabolomics analysis showed that
aspartame was rapidly metabolized and related to SCFA
production, especially propionate production. Changes in
the microbial composition were observed in animals that
received aspartame; the total bacteria and abundance of
Enterobacteriaceae andClostridium leptum increased (28). In
addition, mice treated with aspartame for 11 wk developed
glucose intolerance, although analyses of the microbiota did
not show significant differences between the groups (15).
To our knowledge, there are no data on the potential
influences of aspartame on the human gut microbiome. It
is hard to understand how aspartame influences the gut
microbiota because this NNS is rapidly hydrolyzed in the
small intestine. In fact, even with the ingestion of very high
doses of aspartame (>200 mg/kg), no aspartame is found
in the blood because of its rapid breakdown (29). Upon
ingestion, aspartame breaks down into residual components,
including aspartic acid, phenylalanine, and methanol and
their components, which are readily absorbed so that they do
not reach the large bowel (30).
Neotame and advantame. Neotame (E-961) is an artificial
sweetener that is between 7000 and 13,000 times sweeter
than sucrose with a structure close to that of aspartame
[i.e., N-N-(3,3-dimethylbutyl-l-α-aspartyl-l-phenylalanine
1-methyl ester)]. The FDA and EFSAhave approved neotame
for general use. The suggested ADI is 0.3 mg  kg body
weight−1  d−1. Neotame ismoderately heat stable, extremely
potent, rapidlymetabolized, completely eliminated, and does
not appear to accumulate in the body. Mice and other test
animals fed neotame did not show adverse physical symp-
toms, water consumption, or clinical pathology evaluations
and there were no reports of morbidity, mortality, organ
toxicity, ormacroscopic ormicroscopic postmortemfindings
(31–33).
Advantame (E-969), approved in 2013 by the EU, is an
N-substituted derivative of aspartame made from aspartame
and vanillin and is ∼20,000 times sweeter than sucrose (34).
In 2013, the EFSApanel established anADI of 5mg  kg body
weight−1  d−1 and recognized this sweetener as nontoxic,
noncarcinogenic, and safe for consumption as a food additive
(7).
Neither sweetener has been evaluated in animals or
in humans because only trace amounts of advantame or
neotame are needed to sweeten foods. The amount of
methanol derived from the intestinal hydrolysis of neotame
is much lower than that found in common foods; therefore, it
is improbable that either neotame or advantame would have
any influence on the gut microbiota.
Cyclamate. Cyclamate is used in >50 countries; the
EU approved cyclamic acid and its sodium and calcium
salts for food use (E952), whereas the FDA removed its
Generally Recognized As Safe status in 1969 and it was
completely banned in 1970 (5). This was because of the
detection of bladder tumors in rats fed a cyclamate-saccharin
mixture supplemented with cyclohexylamine, a metabolite
of cyclamate that is more toxic than cyclamate alone (35,
36). However, these studies were severely criticized because
of their designs and doses (37) and cyclamate is being
reevaluated. In the EU, theADI for cyclamate is 7mg/kg body
weight (5, 7).
The first finding of microbiota changes caused by cy-
clamate was reported in the study by Drasar et al. (38).
The authors observed that the conversion of cyclamate to
cyclohexylamine in rats does not occur after either parenteral
administration of cyclamate or with incubations of cyclamate
with the liver, spleen, kidney, or blood preparations. The
principal hypothesis was that cyclohexylamine formation
occurred solely in the gut as the result of microorganism
metabolism (38).
In 1985, Mallett et al. (39) tested the metabolic cyclamate
adaptation on rat gut microbiota maintained in vitro in an
anaerobic culture system. They found amaximum formation
of cycloheximide at 8 wk and increased levels of sulfamatase
activity in the fecal content. The authors did not find any
taxonomic changes in the fecal microbiota cultured in an in
vitro system after the administration of cyclamate.
The presence of cyclamate decreased the fermentation
of glucose by the microbiota in Cara rats (22). Cyclamate
increases the bacterial sulfatase activity in the intestine (40).
To our knowledge, there are no available data on the effects
of cyclamate on gut microbiota in humans.
Saccharin. A range of food and beverages are sweetened
by saccharin (E-954), which is considered safe despite contro-
versial debate about its potential carcinogenicity. However,
studies indicate that the consumption of saccharin might
perturb the gut microbiota. Its ADI is the lowest of all the
intensive sweeteners (5 mg/kg body weight) (5).
The effect of 7.5% saccharin on aerobic and anaerobic
microbial populations from rat cecums over 10 d was tested.
The rats consumed ∼90 mg saccharin, which was detected
in the cecal contents at the end of the intervention. The
presence of saccharin did not alter the total numbers of
anaerobic microbes but resulted in the elimination of a
specific anaerobic group of microbes from the cecal contents
(41).
Saccharin administration inhibited the growth of 6 bac-
terial strains (3 Lactobacillus species and 3 Escherichia coli
strains) isolated from the small intestinal contents in rats
that received a 2.5% dose of saccharin; the rats consumed
107.0 mg saccharin in the diet (rat weights were between
200 and 220 g) (42). Saccharin inhibited the fermentation of
glucose by the microbiota from Cara rats (22).
Pyrosequencing studies in animals showed that the
addition of saccharin plus neohesperidin dihydrochalcone
increases the abundance of the Lactobacillus cecal population
and increases intraluminal lactic acid concentrations (43).
16S ribosomal RNA gene analyses identified 25 major
families encompassing 7 bacterial classes with Bacteroidia,
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animals that received saccharin/neohesperidin dihydrochal-
cone, there were significant shifts in microbial composition,
establishing a major influence driving bacterial community
dynamics (44).
The deleterious metabolic effects of saccharin in animals
were abrogated by antibiotic treatment and were fully trans-
ferrable to germ-free mice upon microbiota transplantation.
In addition, the altered metabolic pathways were linked
with glucose tolerance and dysbiosis in healthy human
subjects. In mice fed saccharin, Akkermansia muciniphila, a
commensal bacterium that exhibits probiotic properties, was
underrepresented (15). Since the study by Suez et al. (15) the
scientific focus has moved toward evaluating the impact of
saccharin on gut microbiota diversity.
Sweeteners are often used to encourage the consumption
of agents such as ethanol and nicotine in laboratory studies
that use rodents. Labrecque et al. (45) evaluated the effect of
ethanol in either water or saccharin on the fecal microbiome
in pregnant and nonpregnant mice. Saccharin reduced
Clostridium numbers, even though the total amounts of
ethanol consumed were the same for the 2 groups (45).
Inflammation is frequently associated with disruptions to
the gut microbiota. Mice treated with 0.3 mg saccharin/mL
(a dose equivalent to the FDA-approvedADI for humans) for
6 mo had increased expression of TNF-α and the inducible
isoform of NO synthase (iNOS) in their livers. In addition,
altered gut bacterial genera were associated with saccharin-
induced liver inflammation. These changes in the intestinal
microbiota were observed in Ruminococcus, Adlercreutzia,
Dorea, Corynebacterium, Roseburia, and Turicibacter (46).
Early studies suggest that artificial sweeteners maintain
plasma glucose and peak insulin concentrations without
affecting the gut microbiota. However, more recent animal
and human studies showed specific changes in the intestinal
microbiota related to alterations in the metabolic pathways
linked to glucose tolerance and dysbiosis in human subjects,
especially with the ingestion of saccharin (Figure 1).
Sucralose. Sucralose (E-955) is a synthetic sweetener
derived by the substitution of the 3 hydroxyl groups in
sucrose and is ∼320–1000 times sweeter than sucrose (47).
Its ADI is 5mg/kg body weight. The first study that evaluated
sucralose on the intestinal microbiota was performed in
2008 with the use of fecal samples from Sprague-Dawley
rats that received the sweetener for 12 wk. The consumption
of sucralose decreased the total number of anaerobic and
aerobic bacteria, bifidobacteria, lactobacilli, Bacteroides, and
Clostridium (48). The administration of 15 mg sucralose/kg
affected the relative abundance of the Clostridium cluster
XIVa in mice (49).
More recently, the administration of sucralose in mice
produced modifications in the intestinal microbiota at
14 different taxonomic levels, including Turicibacteraceae,
Lachnospiraceae, Ruminococcaceae, Verrucomicrobiaceae,
Staphylococcaceae, Streptococcaceae, Dehalobacteriaceae,
Dehalobacterium, Lachnospiraceae, Clostridiaceae, Chris-
tensenellaceae, Peptostreptococcaceae, Erysipelotrichaceae,
FIGURE 1 Effects of artificial sweeteners and saccharin on gut
microbiota. Animal studies have reported specific shifts in the
intestinal microbiota related to alterations in the metabolic
pathways linked to glucose tolerance after ingestion of saccharin.
and the order Bacillales, and changes in the synthesis and
regulation of amino acids. These variations were related to
inflammation in the host (50). The main reported effects
of synthetic sweeteners on the gut microbiota are listed in
Table 2.
Effects of natural sweeteners on the gut microbiota.
Natural sweeteners are sweeter than sucrose, contribute few
calories, have no carcinogenic effects, and do not affect
insulin production (5).
Steviol glucosides. Stevia rebaudiana is a shrub belonging
to the family Ateracea (native to South America), whose
leaves contain diterpene glycosides such as stevioside, stevi-
olbioside, rubusoside, dulcoside A, and rebaudiosides A, B,
C, D, E, F, and M. Its extracts are used as natural noncaloric
sweeteners because it is 250 times sweeter than sucrose (51),
although only highly purified steviol glycosides are approved
for use in food in the EU (7).
Stevioside extracts from S. rebaudiana are not carcino-
genic in the adult population (52). Steviol glycosides are
sweet, low in calories, and noncarcinogenic, but consuming
more than the ADI limit of 4 mg  kg body weight−1  d−1 is
unsafe (EU regulation 1129/2011) (53, 54).
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TABLE 2 Effects of synthetic sweeteners on gut microbiota1
Sweetener and
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weight−1 · d−1
16S rRNA and GC The population of Bacteroides was
highly increased in acesulfame
K–treated male mice, with
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Suez et al. (15) Mice/human
trial
120 mg saccharin 16S rRNA Alterations in metabolic
pathways linked to glucose
tolerance and dysbiosis in
healthy human subjects.







qRT-PCR analysis Eubacteria were increased in
the pregnant group that
received ethanol plus
saccharin and the presence
of saccharin reduced
Clostridium counts.
Reduction in Clostridium was
almost 50%
Bian et al. (46) Mice 0.3 mg/mL in
drinking water
16S rRNA Altered gut bacterial genera
were associated with the
saccharin-induced liver
inflammation.
iNOS and TNF-α increased by
3 and 2 times, respectively.
Intestinal microbiota





by more than twice
Neotame (E-961) — — — No effects on gut microbiota. No changes
Advantame
(E-969)














The decrease was >2-fold
Uebanso et al.
(49)








The inhibition was >50%
1iNOS, inducible NO synthase; 16S rRNA, 16S ribosomal RNA.
Several in vitro studies have investigated how the compo-
nents of stevia extract are metabolized. The data show that
the microbiota (no differences found between humans and
rats) are able to degrade the main components, stevioside
and rebaudioside A, to steviol (55, 56). Therefore, neither
stevioside nor rebaudioside A is absorbed in the upper
gastrointestinal tract (30).
Bacteroides are the most efficient group of bacteria at
hydrolyzing stevioside and rebaudioside A to steviol (56).
Other bacterial groups, such as lactobacilli, bifidobacteria,
Clostridium, coliforms, and enterococci species, were tested.
None of the tested bacteria were able to hydrolyze and use
steviol glycosides as a usable substrate (56). These tested
bacterial groups are the major types of bacteria found in the
gastrointestinal tracts of animals and humans (57).
In addition, compared with glucose, 24 h incubation of
mixed fecal bacteria from volunteers with stevioside and
rebaudioside A caused a slight alteration of the human mi-
crobiota (56). Stevioside weakly inhibits anaerobic bacteria,
whereas rebaudioside A weakly inhibits aerobic bacteria, in
particular over coliforms.
The roots of S. rebaudiana contain inulin and fructans,
functional food ingredients that have a positive effect on
human health (30). The fermentation capacity of fructans as
a substrate for microbiota is strain specific. Fructans derived
from S. rebaudiana, especially those with a polymerization
degree of <6 (carbohydrates with different-size chain), im-
proved the growth of select microbial strains (bifidobacteria
and lactobacilli) that are important for bowel function (58).
Glycyrrhizin. Glycyrrhizin comes from the roots and
rhizome of Glycyrrhiza glabra. It is 30–200 times sweeter
than sucrose and is considered safe if <100 mg/d is ingested.
Glycyrrhizin has anticancer, anti-inflammatory, antioxidant,
antiviral, and hepatoprotective properties. However, it has
potential hypertensive effects and an intense aftertaste (59).
In the gut, glycyrrhizin is de-glycosylated to glycyrrhetic
acid (themajor product) byEubacterium spp. andBacteroides
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J-37 and to 18β-glycyrrhetic acid 3-O-monoglucuronide
(the minor product) by Bacteroides J-37 and Streptococcus
LJ-22. The conversion of 18β-glycyrrhetic acid 3-O-
monoglucuronide to glycyrrhetic acid can also be mediated
by Eubacterium spp. (59–61). These glycyrrhizin metabolites
(especially 18β-glycyrrhetinic acid) are potent cytotoxicity
agents against tumor cells and they exert potent inhibitory
effects on rotavirus infection and antiplatelet aggregation
activity (62).
Some data suggest that the relation between glycyrrhizin
and the intestinal microbiota exerts positive effects on the
host (60, 61, 63). Better-designed studies are needed to
determine if this is truly the case and what the implications
of its metabolism and its mechanism of action and effects are
on the composition of the intestinal microbiota.
Neohesperidin dihydrochalcone, thaumatin, and monellin.
Neohesperidin dihydrochalcone is a natural sweetener ob-
tained from the skin of immature citrus fruits and is
only ∼1500 times sweeter than sucrose. Neohesperidin
dihydrochalcone is metabolized by intestinal microbiota to
innocuous products (5, 53). Thaumatin is a sweet protein
isolated from the fruit of Thaumatococcus daniellii Benth, a
plant native to tropical West Africa. Thaumatin is 100,000
times sweeter than sucrose (5). Monellin is a sweet protein,
naturally extracted from the fruit of the serendipity berry
shrub (64). To our knowledge, there are no ongoing or past
studies ascertaining the potential effects of those natural
sweeteners on the intestinal microbiota.
In summary, natural sweeteners have only a few studies
associating their consumption with changes in the intestinal
microbiota. Stevia extracts have the most information with
regard to their effects on the gut microbiota composition,
although the current effects of stevia on Bacteroides need
further study (Figure 2).
Effects of nutritive LCSs on the gut microbiota
Polyols.
Polyols are a specific group of compounds used as food
additives. They are stable at high temperatures and through
pH changes and do not intervene in Maillard reactions.
A number of polyols are naturally present in some fruits,
vegetables, and mushrooms. Their industrial production
started in the last century with the hope of solving health
problems related to excessively consumed NNSs. Polyols are
noncariogenic, do not induce salivation, and do not interfere
with insulin concentrations or increase the blood glucose
response; therefore, they are used in “light” foods. The FDA,
Codex Alimentarius, and EFSA have approved 8 different
polyols—erythritol, hydrogenated starch hydrolysates, iso-
maltose, lactitol, maltitol, mannitol, sorbitol, and xylitol—for
use as bulk sweeteners in human foods (5, 7, 65, 66).
The excessive consumption of polyols causes gastroin-
testinal symptoms and laxative effects in healthy patients.
Polyols also induce dose-dependent symptoms of flatulence,
abdominal discomfort, and laxative effects when consumed
by both healthy volunteers and patients with irritable bowel
syndrome (IBS). In addition, moderate doses of polyols
increase the number of bifidobacteria in the microbiomes
of healthy individuals and may therefore be beneficial as a
prebiotic, but the data are limited to patients with a number
of intestinal diseases, including IBS (66). It is important to
know the impact of polyol consumption on gut microbiota
both in healthy and diseased humans.
As with all food additives, the safety of polyols is being
re-evaluated by the EFSA. In June 2017, the EFSA called for
technical and toxicologic data on sweeteners authorized as
food additives in the EU.This re-evaluationwill be completed
by the end 2020 (67).
Erythritol. Erythritol (E-968), a four-carbon sugar al-
cohol, occurs widely in nature and in foods such as
wine, beer, mushrooms, pears, grapes, and soy sauce (68).
Industrially, it is produced from glucose by an osmophilic
yeast and subsequently, by separation and purification, yields
a crystalline product with a purity of 99% (69). The estimated
daily intake of erythritol is 1.24 g (53). Oral microorganisms
do not metabolize erythritol and the in vitro incubation of
erythritol with Streptococci species does not produce lactic
acid or other organic acids (70, 71).
Erythritol is rapidly absorbed in the small intestine
by passive diffusion, it is scattered widely through tissues
with minimum metabolism, and finally, it is quantitatively
excreted in the urine (68). Hence, erythritol does not affect
plasma glucose or insulin concentrations or gut microbiota
(72, 73). Despite the adjustment and consideration of all
the fermentation variables (e.g., gas production, hydrogen
accumulation, pH, SCFA production, and substrate degra-
dation), erythritol is completely nonfermentable by freshly
collected human fecal microbiota within a period of 24 h
(71). Although there is no evidence on the effects of erythritol
on gut microbiota in humans in clinical trials, erythritol
is considered a safe additive after many specific tests on
its toxicity, carcinogenicity, and reproductive hazards were
found to be negative (5).
Isomaltose. Isomaltose, isomaltitol, or isomalt (E-953)
is a polyol used worldwide as a sugar replacement with
technological properties comparable to those of sucrose.
Isomaltose is used in bubble gums, gelatins, chocolate,
coatings, baked goods, and yogurts. Isomaltose is obtained
through the enzymatic transformation of sucrose, is stable
at high temperatures, and has a very low hygroscopic value.
Moreover, it is low in energy, noncariogenic, and is as sweet
as other polyols. Undigested or unabsorbed portions of
isomaltose reach the colon and are fermented by the gut
microbiota; the fermented fraction of ingested isomaltose is
∼90% (5, 17, 74, 75). Isomaltose is considered a prebiotic
carbohydrate that might contribute to a healthy luminal
colonic mucosal environment. During 4-wk periods in a
double-blind, placebo-controlled, crossover-design clinical
trial, 19 healthy volunteers consumed a basal diet enriched
with either 30 g isomaltose or 30 g sucrose/d and found
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FIGURE 2 Natural sweeteners and their effects on gut microbiota. Stevia extracts have been described as capable of changing the gut
microbiota composition, although the current effects of stevia on Bacteroides need further study.
(75). Later, it was reported that isomaltose fermented in
the gut increased bifidobacteria and decreased bacterial
β-glucosidase, whereas β-glucuronidase, sulfatase, nitrore-
ductase, and urease remained unchanged. Fecal SCFAs,
lactate, bile acids, neutral sterols, nitrogen, ammonia, phenol,
and p-cresol were not affected by isomaltose consumption. In
addition, in vitro, several bifidobacteria strains were capable
of metabolizing the isomaltose and generated high butyrate
concentrations (76). Moreover, at the end of each test phase,
rectal biopsy samples were taken and gene expression was
measured bymicroarray and qRT-PCR. Dietary intervention
with low digestible isomaltose compared with digestible
sucrose did not affect gene expression in the rectal mucosa
lining (77). Hence, isomaltose is a polyol with bifido-
genic properties that might contribute to a healthy colonic
environment.
Lactitol. Lactitol (E-966) is a non–naturally occurring
sugar alcohol, which is obtained by the hydrogenation of
lactose. Compared with the other polyols, its sweetening
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power is limited and consequently it is usually used in
combination with intense sweeteners (5). This disaccharide
is normally not absorbed in the small intestine (78) because
of the lack of a suitable β-galactosidase and, as a result, it
reaches the lower gut where it is fermented (79). Therefore,
it makes a caloric contribution of <2% (31). However,
higher lactitol intakes can produce laxative effects; studies
showed that lactitol promotes the growth of bifidobacteria
and lactobacilli. On the other hand, fermentation of lactitol
by saccharolytic bacteria has also been shown to decrease
counts of proteolytic bacteria, such as Bacteroides, col-
iforms, Enterobacteria, and Enterococci (80). In vitro, lactitol
(2 mg/L) reduces the Enterobacteriaceae population in
feline fecal cultures and exerts a prebiotic effect on feline
intestinal microbiota (81). Ballongue et al. (82) showed that
lactitol treatment over 9 wk decreased bacterial populations
of Bacteroides, Clostridium, coliforms, and Eubacterium.
Lactitol also causes a decrease in fecal pH (82). In rats, lactitol
increases the production of butyrate and IgA secretion
without signs of mucosal inflammation (83). In the elderly,
the consumption of lactitol as a synbiotic, combined with
Lactobacillus acidophilus NCFM, improves some intestinal
microbiota markers andmucosal functions (84). In addition,
the synbiotic products of L. acidophilus NCFM and lactitol
decrease the abundance of theBlautia coccoides–Eubacterium
rectale bacterial group and Clostridium cluster XIVab counts
(85). Another study by Finney et al. (86) showed that low
doses of lactitol consumed as a sweetener (10 g) beneficially
affect the fecal microbiota, increasing bifidobacteria and
concentrations of the volatile propionic and butyric acids,
without eliciting gross symptoms of intolerance; it is a
prebiotic (86). These data suggest that lactitol is useful as a
prebiotic for enhancing the gut microbiota, is noncariogenic,
and is of mild sweetness. For many, compared with lactulose
or other sweeteners, the low sweetness of lactitol is an
advantage of lactitol supplementation compared with others
such as lactulose (80).
Maltitol. Maltitol (E965) is obtained by the hydrolysis,
reduction, and hydrogenation of starch, resulting in a
sweetener with ∼90% sweetening capacity. Maltitol most
resembles the flavor of sugar, is noncariogenic, and safe for
diabetics. It has a similar solubility and hygroscopicity to
sucrose and is the preferred sugar for use in the production
of no-sugar-added–labeled chocolate (5, 87). Maltitol has
a very slow digestion rate because it is fermented in the
colon. Therefore, it is expected that it could be fermented
by the gut microbiota. In a human study, 40 volunteers
consumed a test chocolate containing 22.8 gmaltitol, maltitol
plus polydextrose, or maltitol plus resistant starch for 14
consecutive days. The doses of the test chocolates were
doubled every 2 wk over a 6-wk period. The authors
evaluated the impact of confectionary sweeteners on the
composition of gut microbiota and, at an optimal dose of
34.2 g for maltitol plus polydextrose, the numbers of fecal
bifidobacteria, lactobacilli, and SCFAs significantly increased
after the ingestion of maltitol compared with the ingestion of
sucrose (88). However, to date, there are not enough data to
determine the specific effects of maltitol on gut microbiota.
Sorbitol. Sorbitol (E-420), also known as d-glucitol, is
an isomeric polyol whose production is based on the
catalytic hydrogenation of glucose with subsequent purifi-
cation. Sorbitol is found naturally in apples, pears, peaches,
apricots, and some vegetables (65); and although there is
no evidence of sorbitol toxicity, a possible association of
sorbitol with genotoxicity and shifts in metabolism in rats
fed sorbitol has been reported. In healthy people, 71%
show malabsorption after the consumption of 10 g sorbitol
and 20% had gastrointestinal symptoms (89). In addition,
patients with IBS have adverse gastrointestinal reactions to
polyols, especially sorbitol and mannitol (independent of
the absorption patterns of each molecule). Although sorbitol
can be of concern for patients with IBS, it seems to be
safe for healthy individuals, although there are reports of
laxative effects when consumed in high doses (5, 90). Most
healthy individuals tolerate ∼10 g sorbitol/d with only mild
gastrointestinal discomfort, such as flatulence or bloating.
However, doses of 20 g sorbitol/d can evoke more distressing
symptoms of abdominal pain and diarrhea (66, 91). Sorbitol
is usually less tolerated than lactitol because sorbitol exerts
a greater osmotic load in the gastrointestinal tract, leading
to an increased concentration of water in the colon and,
consequently, greater laxative effects (92, 93). However, to
date, there are not enough data to definitively determine the
effects of sorbitol on gut microbiota.
Mannitol. Mannitol (E-421) is an isomer of sorbitol and
is obtained from the hydrogenation of glucose and its
consequent purification. Although less sweet than sorbitol,
mannitol is also used in food because it has a high metabo-
lization ratio (the ratio of a drug metabolite concentration to
its parent drug concentration, expressed as a range) of∼75%;
the other 25% is absorbed before being excreted in the urine.
Because it is virtually inert (i.e., it does not react with active
components of drugs) and confers a cool sweet taste, apart
from being used in the food industry it is also widely used
in dental hygiene products, drug fillers, and as a diuretic in
intravenous fluids (5, 17, 31, 94, 95). To our knowledge, no
data on the effects of mannitol on the gut microbiota are
available.
Xylitol. Xylitol (E-967), a five-carbon polyol, obtained
by the hydrogenation of d-xylose is naturally found in
fruits, berries, vegetables, oats, and mushrooms and a small
percentage is also produced by the human body. Xylitol is
widely used in various pharmaceutical products in addition
to sugar-free candies and chewing gums. Xylitol was first
synthesized in 1891 and is ∼95% as sweet as sucrose (5, 66).
The effects of intakes of 40 and 200 mg xylitol · kg body
weight−1 · d−1 on the composition of gut microbiota and
lipidmetabolism inmice have been reported. Xylitol reduced
the abundance of fecal Bacteroidetes and Barnesiella and
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fed a high-fat diet with medium-dose dietary xylitol (49).
Because xylitol is capable of modifying the gut microbiota in
mice, a study by Tamura et al. (96) compared the fecal micro-
biome of mice after being fed either a 0.05% isoflavone and
5% xylitol diet or a 0.05% isoflavone-only diet as a control.
The Bacteroides concentration was higher in the control diet
than in the xylitol-rich diet (96). In addition, xylitol ingestion
shifted the rodent fecal microbiome population from Gram-
negative to Gram-positive bacteria. In human volunteers, a
similar shift occurs after a single 30-g oral dose of xylitol
(97). The effect of soluble low-digestible carbohydrates,
including xylitol, on butyrate production and the prebiotic
potential of these substances has been assessed using in
vitro human fecal cultures. l-Sorbose and xylitol cause
prebiotic stimulation of the growth and metabolic activity
of Anaerostipes spp. in the human colon (98). The cor-
relation between bacterial translocation with morphologic
changes in the intestinal mucosa and shifts of the intestinal
microbiota in hamsters with Clostridium difficile infection
show that the combination of lactobacilli (probiotic) and
xylitol (prebiotic) had a protective effect against C. difficile
infection (99).
To conclude, although some polyols, such as erythritol,
sorbitol, and mannitol, do not affect the composition of
gut microbiota, moderate doses of polyols could induce
shifts in the gut microbiome in healthy people. The laxative
effects of polyols need to be considered when they are
consumed by patients with inflammatory bowel disease.
The effects of polyols are described in Table 3. In addi-
tion, Figure 3 summarizes the effects of polyols on gut
microbiota.
Effects of sweeteners on the gut microbiota in human
trials
Sweeteners are used in many food processes, and the
impact of the consumption of these kinds of compounds
affects health status and microbiota composition. Today,
the potential modifications of the intestinal microbiome,
mediated by specific sweeteners, in healthy adults or children
are a matter of concern. However, there are few clinical
studies.
The study by Suez et al. (15) in 2014 showedmodifications
in the intestinal microbiota after the administration of
some sweeteners [especially noncaloric artificial sweeten-
ers (NASs)] from data collected on 172 randomly se-
lected individuals. They found positive correlations between
NAS consumption and the Enterobacteriaceae family, the
Deltaproteobacteria class, and the Actinobacteria phylum.
In addition, they followed 7 healthy volunteers who did
not normally consume NASs or NAS-containing foods for
1 wk. In that week, the volunteers consumed the maximal
ADI of saccharin (5 mg/kg). Compared with their individual
glycemic response on days 1–4, the volunteers in the NAS
group showed decreased glycemic responses at days 5 and
7 (15). The magnitude of the difference was >30%. These
findings suggest that NAS consumption, and especially
saccharin at a maximum dose, might have a deleterious
effect on glucose tolerance through changes to the intestinal
microbiota. There is a current controversy in the scientific
field with regard to the Suez et al. study because of the control
groups, the use of antibiotics, and the fecal transplantations
that were used (100). Nevertheless, the simple message from
this study is that dietary sugar alternatives meant to stave off
the risk of obesity and diabetes might increase the risk of
those diseases.
In another study, 31 adults completed a 4-d food record
and provided a fecal sample on the fifth day. Their in-
testinal microbiota were analyzed by pyrosequencing. The
abundance profiles were not associated with sweetener
consumption, especially with aspartame. However, the over-
all bacterial diversity varied across both consumers and
nonconsumers of sweeteners (23).
Conclusions
Growing concerns about the increased prevalence of obesity
and its metabolic comorbidities have led to a reduced
consumption of simple sugars and an increase in the intake
of NNSs and LCSs. Thus, sweeteners, which appear as
sugar alternatives, have been critically evaluated by the FDA,
EFSA, and Codex Alimentarius and are considered safe
and well tolerated. However, some long-term prospective
studies raise the concern that the consumption of artificial
sweeteners might actually contribute to the development
of metabolic derangements that lead to obesity, T2D, and
cardiovascular disease (101). In addition, there are gaps in
the evidence related to the effects of NNSs on appetite,
short-term intake, and risk of cancer and diabetes (2).
The effects of sweeteners on gut microbiota have not
been completely elucidated. Within NNSs, only saccharin
and sucralose shift the populations of gut microbiota. The
ingestion of saccharin by animals and humans showed
alterations in metabolic pathways linked to glucose tolerance
and dysbiosis in humans. However, more human studies
are needed to clarify these preliminary observations. Within
nutritive sweeteners, only stevia extracts may affect gut
microbiota composition. Finally, polyols, as they reach the
colon, can induce dose-dependent flatulence, especially in
patients with inflammatory bowel disease. Several polyols,
including isomaltose and maltitol, increase bifidobacteria
numbers in healthy subjects, and these polyols may have
prebiotic actions. On the other hand, different human
clinical trials showed that lactitol decreases the populations
of Bacteroides, Clostridium, coliforms, and Eubacterium. In
addition, lactitol increases the production of butyrate and
IgA secretion without signs of mucosal inflammation and
presents symbiotic effects. Xylitol reduces the abundance
of fecal Bacteroidetes and the genus Barnesiella, increases
Firmicutes and the genus Prevotella, and affects C. difficile in
mice.
Further studies are needed to elucidate whether the
changes observed in the intestinal microbiota in animals are
present in humans and to study the effects of sweeteners
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FIGURE 3 Effects of polyols on gut microbiota composition. Erythritol, sorbitol, and mannitol do not affect the composition of the gut
microbiota; however, lactitol, isomaltose, xylitol, and maltitol provoke shifts in the gut microbiome, increasing bifidobacteria numbers in
healthy people. The laxative effects of polyols need to be considered when they are consumed by patients with inflammatory bowel
disease. C. difficile, Clostridium difficile; N/A, not available.
for which evidence is not available so far. In this regard,
there is an actual need to perform well-designed, long-term,
double-blind, placebo-controlled, randomized clinical trials
with appropriated doses and adequate subject sizes to evalu-
ate the potential impact of both NNSs and LCSs on intestinal
microbiota and how they could affect major outcomes and
risk biomarkers related to chronic diseases.
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